Guess which ASX All Ords share is crashing 30% today

Investors have been hitting the sell button in a panic on Friday.

The Integral Diagnostics Ltd (ASX: IDX) share price is having a day to forget on Friday.

At the time of writing, the ASX All Ords share is down 30% to $1.86.

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.

Image source: Getty Images

Why is this ASX All Ords share crashing?

Investors have been scrambling to the exits today after the medical imaging services provider released a very disappointing trading update.

According to the release, first-quarter revenue growth of 8.4% was achieved in Australia compared with the prior corresponding period.

As a comparison, management highlights that Medicare benefits for the states in which Integral Diagnostics operates have seen a 9.5% increase in the weighted average benefits paid, adjusted for working days.

Over in New Zealand, the company achieved a 4.1% increase in constant currency revenue compared with the prior corresponding period.

However, this growth appears to have been offset by higher-than-expected labour costs which have impacted its operating EBITDA. This has been driven by clinical staff shortages, particularly in regional areas, and cost inflation.

In light of this, the ASX All Ords share has not seen the expected operating EBITDA margin improvement it was expecting.

Management advised that it is responding to these pressures by accelerating productivity and efficiency initiatives. These actions are expected to lead to an improvement in its margin performance in the second half.

The company hasn't provided any earnings guidance for the half (or full year) but has given investors an idea of what to expect in respect to capex, depreciation, and finance costs.

Replacement and growth capex is to be in the range of $30 million to $40 million in FY 2024. Whereas depreciation of ~$45 million and finance costs of ~$22 million are forecast for the 12 months. The latter assumes that the Reserve Bank will increase rates by a further 0.25% next week.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

The hunt for Australia's next CSL: 3 ASX healthcare shares with enormous potential

I look at three healthcare businesses that could be much larger companies in the years ahead.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Should I invest $2,000 into Mesoblast shares?

I look at whether commercial progress has made this long-awaited biotech story worth investing in today.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Pro Medicus vs Telix Pharmaceuticals: Which is more likely to double your money in 2 years?

Can Pro Medicus or Telix Pharmaceuticals double your money on the ASX? We stack up their value, growth, and price…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL has a new CEO. Are its shares a buy?

I look at what the incoming CEO could bring to the business as its recovery continues.

Read more »

Man holding a calculator with Australian dollar notes, symbolising dividends.
Healthcare Shares

Forget term deposits! I'd buy these ASX dividend shares instead

Term deposits are not exciting to me because of one key reason.

Read more »

A sobbing businessman accused of wrongdoing faces justice
Healthcare Shares

CSL responds to class action, defends disclosure record

The CSL share price is under the microscope after it revealed it will defend a newly filed class action lawsuit.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Up 13%: Why is everyone buying Pro Medicus shares this week?

The ASX healthcare shares jumped another 3% on Wednesday.

Read more »

healthcare worker overseeing group of aged care residents at table
Healthcare Shares

Regis Healthcare vs Ryman Healthcare: Which under-the-radar ASX small-cap could double from here?

We compare Regis Healthcare and Ryman Healthcare shares to find out which aged care small-cap could bounce back faster.

Read more »